In this phase 2 trial, tulisokibart (a tumor necrosis factor–like cytokine 1A monoclonal antibody) was more effective than placebo in inducing clinical remission in patients with ulcerative colitis.
The New England Journal of Medicine: Search Results in Allergy/Immunology
